Sign in
CompletedPhase 2/3

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

Key facts

Who runs it
Bassett Healthcare
Where
Cooperstown, Portland, and Springfield, United StatesSee the 3 sites
Trial code
Status
Completed
Phase
Phase 2/3
People taking part
15 people enrolled
Started
3 Apr 2020
Ended
1 Oct 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Baloxavir
  • Placebos
Record updated
14 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Adults >/= 18 years old
  • Laboratory confirmed influenza A and/or B (rapid test or PCR)
  • Able to be enrolled, randomized, and dosed with study drug within 8 hours of the decision to admit patient to hospital for treatment of influenza
  • Oseltamivir treatment ordered by clinical team AND patient is able to be enrolled:; Prior to the initial dose of oseltamivir OR; Within 60 minutes after the initial dose of oseltamivir
  • Subject or Legally Authorized Representative able to and willing to provide written informed consent
  • Able to commit to 30 days of follow up
  • Weight > 40 kg
  • SARS-CoV-2 PCR swab sent within 1 week of enrollment

Who cannot take part

  • Influenza medication use within the prior week, other than the initial oseltamivir given during this hospitalization for this episode of influenza
  • Refusal of oseltamivir therapy by patient as baseline treatment
  • Severe hepatic insufficiency, cirrhosis, acute or chronic liver failure
  • Nausea/vomiting, aspiration risk, or other conditions precluding the ability to use oral medications (if patient is NPO including meds, otherwise unable to swallow oral medications)
  • Oseltamivir or baloxavir allergy or intolerance
  • Pregnancy (need negative pregnancy test (urine or blood) in reproductive age women)
  • Absence of dependable contraception in reproductive age women
  • ESRD not undergoing hemodialysis (HD) or peritoneal dialysis (CAPD)
  • Inability to obtain informed consent

Where in United States

  • Bassett Medical CenterCooperstown, United States
  • Oregon Health Science UniversityPortland, United States
  • Baystate Medical CenterSpringfield, United States

About the trial

What the trial wants to find out

This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).

The 2 groups in the trial

  • baloxavirTreatment being tested

    Baloxavir: 40 mg po once for wt \< 80 kg OR 80 mg po once for wt \>/= 80 kg

  • placeboPlacebo, for comparison

    placebo po once

    Treatment: Placebos

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
14 May 2026